GUANGZHOU, China, Oct. 05, 2026 (GLOBE NEWSWIRE) — YSX TECH. CO., LTD (NASDAQ: “YSXT”) (the “Company”), a Cayman Islands exempted company that, through its variable interest entities in China, provides comprehensive business solutions mainly for insurance companies and brokerages in China, today announced that it will hold an extraordinary general meeting of shareholders (the “EGM”), on October 19, 2026 at 12:00 a.m. Eastern Time, at Room 102, Building 1, No. 22, Huazhou Road, Haizhu District, Guangzhou, Guangdong, China , for the purpose of considering and voting on the following proposals:

  1. To approve, as an ordinary resolution, that the Company’s authorized share capital be increased, effective immediately, from US$50,000 divided into (i) 470,000,000 Class A ordinary shares of US$0.0001 par value each and (ii) 30,000,000 Class B ordinary shares of US$0.0001 par value each, to US$220,000,000 divided into (i) 2,000,000,000,000 Class A ordinary shares of US$0.0001 par value each and (ii) 200,000,000,000 Class B ordinary shares of US$0.0001 par value each, by the creation and addition of 1,999,530,000,000 authorised but unissued Class A ordinary shares of US$0.0001 par value each and 199,970,000,000 authorized but unissued Class B ordinary shares of US$0.0001 par value each (the “Authorized Share Capital Increase”).
  2. To approve, as a special resolution, that the notice period to members for convening general meetings from fourteen (14) clear days in the case of an annual general meeting and seven (7) clear days in the case of any general meeting other than an annual general meeting, to five (5) clear days for all general meetings (the “Reduction of Notice Period”).
  3. To approve, as a special resolution, that, subject to and immediately following the Authorized Share Capital Increase being effected, the Company adopt an amended and restated memorandum and articles of association, the form of which is attached to the notice of the Meeting as the Appendix in substitution for, and to the exclusion of, the Company’s existing memorandum and articles of association, to reflect, among other things, the Authorized Share Capital Increase, the Reduction of Notice Period and certain housekeeping changes.

The Board of Directors has fixed the close of business on September 30, 2026 as the record date (the “Record Date”) for determining the shareholders entitled to receive notice of and to vote at the EGM or any adjournment thereof. Only the shareholders on the Record Date are entitled to receive notice of and to vote at the EGM or any adjournment thereof.

Shareholders may obtain a copy of the proxy materials from the Company’s website at https://ir.ysxtechcay.com/. The notice of the EGM, the proxy statement, and the proxy card were sent or made available to shareholders on October 2, 2026.

About YSX TECH. CO., LTD

YSX TECH. CO., LTD is a Cayman Islands exempted company that, through its variable interest entities in China, provides comprehensive business solutions mainly for insurance companies and brokerages in China. The Company possesses in-depth knowledge of the Chinese insurance industry accumulated from years of servicing customers, and specializes in auto insurance aftermarket value-added services, software development and information technology services, as well as other scenario-based customized services, such as products and customer development services. For more information please visit: https://ir.ysxtechcay.com and https://www.ysxnet.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the Company’s filings with the United States Securities and Exchange Commission, which are available for review at www.sec.gov. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:
YSX Tech. Co., Ltd
marketing@ysxnet.com
+86 (20) 2984 2002

SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Blaize Holdings, Inc. (Nasdaq: BZAI; BZAIW) (“Blaize” or the “Company”), a leader in programmable, energy-efficient AI computing, today announced its preliminary third quarter 2026 revenue. The Company also provided an update regarding its previously issued full-year 2026 revenue guidance. These matters are further described in a Current Report on Form 8-K filed today with the U.S. Securities and Exchange Commission.

Preliminary Third Quarter 2026 Revenue and Full Year Outlook

The Company expects to report preliminary revenue of approximately $0.5 million for the third quarter ending September 30, 2026.

The Company’s preliminary third-quarter revenue estimate is based on currently available information and remains subject to completion of the Company’s quarter-end closing procedures. Actual results could differ materially from this preliminary estimate.

Given the foregoing and as noted below, the Company is revising its full-year revenue guidance for 2026 to be between $32.0 million and $36.0 million. The revised guidance is based on binding, non-cancellable purchase orders from NeoTensr and a new purchase order from an existing customer in process of signature. The product shipments to NeoTensr this quarter relate to the contract announced by the Company in April 2026 for up to $50.0 million. The revision reflects the Company’s updated expectations regarding shipment timing and management of working capital to meet inventory purchase needs. The Company has sufficient inventory on hand to partially fulfill the orders in the fourth quarter and is working with suppliers to obtain the balance before the year end. Any increased costs that are able to be passed through to customers or new customer commitments received during the fourth quarter that can be fulfilled through inventory on hand or software service agreements and recognized in the quarter would be additive to the Company’s revenue expectations. Should there be delays in timing or in receiving payments from customers scheduled during the fourth quarter, the Company’s revenue recognition for the year could be adversely affected.

About Blaize
Blaize delivers a programmable AI platform, purpose-built for AI inference workloads in real-world environments. Its Hybrid AI architecture combines the Blaize GSP (Graph Streaming Processor) with GPU-based infrastructure, enabling AI inference workloads to run across edge, cloud, and data center. Blaize solutions support computer vision, multimodal AI, and sensor-driven applications across smart cities, industrial automation, telecommunications, retail, logistics, and mission-critical operations. Blaize is headquartered in San Jose, California, with a presence across North America, Europe, the Middle East, and Asia. Visit www.blaize.com or follow us on LinkedIn @blaizeinc.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding the Company’s preliminary estimated revenue for the three months ended September 30, 2026, and the Company’s guidance and expectations for the fourth quarter of 2026.

Forward-looking statements are based on management’s current expectations and are subject to risks, uncertainties and changes in circumstances, many of which are outside the Company’s control. Actual results may differ materially from those expressed or implied by these forward-looking statements. Important factors that could cause actual results to differ materially are discussed in the Company’s filings with the Securities and Exchange Commission, including the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 24, 2026, as amended on April 30, 2026. Forward-looking statements speak only as of the date of this press release, and the Company assumes no obligation to update them except as required by law.

Investors Contact
IR@blaize.com

Media Contact
press@blaize.com

SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Blaize Holdings, Inc. (Nasdaq: BZAI; BZAIW) (“Blaize” or the “Company”), a leader in programmable, energy-efficient AI computing, today announced its preliminary third quarter 2026 revenue. The Company also provided an update regarding its previously issued full-year 2026 revenue guidance. These matters are further described in a Current Report on Form 8-K filed today with the U.S. Securities and Exchange Commission.

Preliminary Third Quarter 2026 Revenue and Full Year Outlook

The Company expects to report preliminary revenue of approximately $0.5 million for the third quarter ending September 30, 2026.

The Company’s preliminary third-quarter revenue estimate is based on currently available information and remains subject to completion of the Company’s quarter-end closing procedures. Actual results could differ materially from this preliminary estimate.

Given the foregoing and as noted below, the Company is revising its full-year revenue guidance for 2026 to be between $32.0 million and $36.0 million. The revised guidance is based on binding, non-cancellable purchase orders from NeoTensr and a new purchase order from an existing customer in process of signature. The product shipments to NeoTensr this quarter relate to the contract announced by the Company in April 2026 for up to $50.0 million. The revision reflects the Company’s updated expectations regarding shipment timing and management of working capital to meet inventory purchase needs. The Company has sufficient inventory on hand to partially fulfill the orders in the fourth quarter and is working with suppliers to obtain the balance before the year end. Any increased costs that are able to be passed through to customers or new customer commitments received during the fourth quarter that can be fulfilled through inventory on hand or software service agreements and recognized in the quarter would be additive to the Company’s revenue expectations. Should there be delays in timing or in receiving payments from customers scheduled during the fourth quarter, the Company’s revenue recognition for the year could be adversely affected.

About Blaize
Blaize delivers a programmable AI platform, purpose-built for AI inference workloads in real-world environments. Its Hybrid AI architecture combines the Blaize GSP (Graph Streaming Processor) with GPU-based infrastructure, enabling AI inference workloads to run across edge, cloud, and data center. Blaize solutions support computer vision, multimodal AI, and sensor-driven applications across smart cities, industrial automation, telecommunications, retail, logistics, and mission-critical operations. Blaize is headquartered in San Jose, California, with a presence across North America, Europe, the Middle East, and Asia. Visit www.blaize.com or follow us on LinkedIn @blaizeinc.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding the Company’s preliminary estimated revenue for the three months ended September 30, 2026, and the Company’s guidance and expectations for the fourth quarter of 2026.

Forward-looking statements are based on management’s current expectations and are subject to risks, uncertainties and changes in circumstances, many of which are outside the Company’s control. Actual results may differ materially from those expressed or implied by these forward-looking statements. Important factors that could cause actual results to differ materially are discussed in the Company’s filings with the Securities and Exchange Commission, including the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 24, 2026, as amended on April 30, 2026. Forward-looking statements speak only as of the date of this press release, and the Company assumes no obligation to update them except as required by law.

Investors Contact
IR@blaize.com

Media Contact
press@blaize.com

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced the pricing of its previously announced underwritten public offering of 4,117,648 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to the Company from this offering are expected to be approximately $350.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional approximately $52.5 million of shares of the Company’s common stock offered in the public offering under the same terms and conditions. The offering is expected to close on or about October 7, 2026, subject to satisfaction of customary closing conditions.

Jefferies, TD Cowen, Leerink Partners and Stifel are acting as the joint book-running managers for the offering. LifeSci Capital is acting as passive bookrunner for the offering.

Spyre intends to use the net proceeds from the proposed public offering to continue to advance its programs in Gastroenterology, Rheumatology, and Dermatology, including to fund preclinical studies, clinical trials, manufacturing, and Phase 3 readiness, as well as a new program to advance SPY072 into late-stage development for hidradenitis suppurativa. Any remaining proceeds will be used for other ongoing research and development, working capital and other general corporate purposes.

A registration statement on Form S-3 (File No. 333-297063) relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and became effective on June 26, 2026. This offering is being made solely by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus related to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ext. 6105, or by email at syndicate@leerink.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre’s pipeline includes investigational extended half-life antibodies targeting a4p7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

Safe Harbor / Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical fact are forward-looking statements. These forward-looking statements include statements regarding Spyre’s expectations regarding the consummation of the offering and the satisfaction of customary closing conditions related to the offering. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “predict,” “target,” “intend,” “could,” “would,” “should,” “project,” “plan,” “expect,” the negatives of these terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, market conditions and satisfaction of customary closing conditions related to the offering, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s interpretation of data and the Company’s ongoing or planned clinical trials for its product candidates; the Company’s ability to elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients; the potential for interim data not being delivered within expected time frames or final data not being consistent with or different than the previously disclosed data reported for the Company’s programs; the expected or potential impact of macroeconomic conditions, including inflationary pressures, rising interest rates, general economic slowdown or a recession, changes in tariff/trade and monetary policy, volatile market conditions, financial institution instability, as well as geopolitical instability, including the ongoing military conflicts between the United States and Iran, Ukraine and Russia, conflicts in the Middle East, and geopolitical tensions between the United States and other countries, including China, on the Company’s operations; the implementation of changes in law, tariffs, sanctions, export or import controls, and other government measures that could impact the Company’s business operations, including restricting international trade by the United States, China or other countries; and those risks described in the Company’s most recent Annual Report on Form 10-K, its subsequent Quarterly Reports on Form 10-Q, as well as in other filings and reports that the Company makes from time to time with the SEC. Moreover, the Company operates in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for the Company’s management to predict all risks, nor can the Company assess the impact of all factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. The Company undertakes no obligation to update publicly any forward-looking statement for any reason after the date of this press release to conform these statements to actual results, to reflect changes in the Company’s expectations, or otherwise, except as required by law.

For Investors:
Eric McIntyre
VP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com

For Media:
Josie Butler, 1AB
josie@1abmedia.com

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced the pricing of its previously announced underwritten public offering of 4,117,648 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to the Company from this offering are expected to be approximately $350.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional approximately $52.5 million of shares of the Company’s common stock offered in the public offering under the same terms and conditions. The offering is expected to close on or about October 7, 2026, subject to satisfaction of customary closing conditions.

Jefferies, TD Cowen, Leerink Partners and Stifel are acting as the joint book-running managers for the offering. LifeSci Capital is acting as passive bookrunner for the offering.

Spyre intends to use the net proceeds from the proposed public offering to continue to advance its programs in Gastroenterology, Rheumatology, and Dermatology, including to fund preclinical studies, clinical trials, manufacturing, and Phase 3 readiness, as well as a new program to advance SPY072 into late-stage development for hidradenitis suppurativa. Any remaining proceeds will be used for other ongoing research and development, working capital and other general corporate purposes.

A registration statement on Form S-3 (File No. 333-297063) relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and became effective on June 26, 2026. This offering is being made solely by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus related to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ext. 6105, or by email at syndicate@leerink.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre’s pipeline includes investigational extended half-life antibodies targeting a4p7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

Safe Harbor / Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical fact are forward-looking statements. These forward-looking statements include statements regarding Spyre’s expectations regarding the consummation of the offering and the satisfaction of customary closing conditions related to the offering. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “predict,” “target,” “intend,” “could,” “would,” “should,” “project,” “plan,” “expect,” the negatives of these terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, market conditions and satisfaction of customary closing conditions related to the offering, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s interpretation of data and the Company’s ongoing or planned clinical trials for its product candidates; the Company’s ability to elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients; the potential for interim data not being delivered within expected time frames or final data not being consistent with or different than the previously disclosed data reported for the Company’s programs; the expected or potential impact of macroeconomic conditions, including inflationary pressures, rising interest rates, general economic slowdown or a recession, changes in tariff/trade and monetary policy, volatile market conditions, financial institution instability, as well as geopolitical instability, including the ongoing military conflicts between the United States and Iran, Ukraine and Russia, conflicts in the Middle East, and geopolitical tensions between the United States and other countries, including China, on the Company’s operations; the implementation of changes in law, tariffs, sanctions, export or import controls, and other government measures that could impact the Company’s business operations, including restricting international trade by the United States, China or other countries; and those risks described in the Company’s most recent Annual Report on Form 10-K, its subsequent Quarterly Reports on Form 10-Q, as well as in other filings and reports that the Company makes from time to time with the SEC. Moreover, the Company operates in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for the Company’s management to predict all risks, nor can the Company assess the impact of all factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. The Company undertakes no obligation to update publicly any forward-looking statement for any reason after the date of this press release to conform these statements to actual results, to reflect changes in the Company’s expectations, or otherwise, except as required by law.

For Investors:
Eric McIntyre
VP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com

For Media:
Josie Butler, 1AB
josie@1abmedia.com

MARLBOROUGH, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) — IPG Photonics today announced that from October 6th though October 8th, 2026, IPG Defense will participate in Land Forces 2026 in Perth, Australia to showcase CROSSBOW™ High-Energy Laser (HEL) Systems. This key industry event provides a platform to forge strategic alliances and collaborate to shape the future of the global aerospace and defense market.

IPG Defense Products at Land Forces 2026

In the IPG Defense booth, visitors will experience both the previously released CROSSBOW MINI and the first addition to the new CROSSBOW SE product line, the CROSSBOW SE1 8 kW. Multiple systems will be on display in a typical layered defense arrangement to showcase several deployment scenarios first-hand. Both products share the same scalable architecture and easily integrate with available radar and C2 systems. CROSSBOW MINI systems allow for rapid expeditionary deployment where mobility is critical, and the CROSSBOW SE product line provides increased laser power options for longer range defense against Group I-III UAS threats.

In addition, interactive kiosks will allow attendees to conduct virtual simulations by placing UAS threats and CROSSBOW laser defense systems into scenes to defend critical assets. This interactive experience provides a detailed example of how IPG Defense products can be deployed to defend against UAS swarms in any environment.

Increased Drone Incursions are Fueling Demand

Military installations, government buildings, public arenas, port complexes and critical infrastructures are but a few of the locations where CROSSBOW laser defense systems provide scalable and cost-effective Counter-UAS protection.

“Across the globe, UAS, whether individually or in swarms, continue to threaten both military and civilian critical assets,” said Dr. Ben Allison, Vice President of IPG Defense. “Our presence here at Land Forces is to engage with customers and showcase how our current product lines address their needs, with particular emphasis on demonstrating cooperative engagements with multiple CROSSBOW systems in a layered defense architecture.”

The IPG Defense booth K05 on Level 3 at Land Forces will be staffed with knowledgeable program personnel who are able to discuss laser defense solutions and IPG Defense products.

For more information please visit: IPGDefense.com

About Land Forces

Held biennially over three days, Land Forces is Australia’s premier platform for advancing land-based defense capability as a platform for engagement, featuring a comprehensive international industry exhibition, a specialist conference program with presentations and symposia from leading defense institutions, and extensive networking opportunities.

As the land domain continues to evolve through investment, and strategic partnerships, Land Forces provides a vital interface for stakeholders to explore capability development, supply chain integration, and future force design.

About IPG Defense

IPG Defense is delivering scalable and cost-effective laser Counter-UAS systems for protection of commercial, government and military critical assets and sites from UAS threats.

About IPG Photonics

Innovation is at the heart of IPG Photonics. As a global leader in laser technology, we apply light to transform the world. From manufacturing to medical and beyond, our breakthrough laser solutions power our customers’ success and expand what’s possible.

Contact
Dr. Ben Allison
VP, IPG Defense Products
+1 256-715-5750
ballison@IPGDefense.com

MARLBOROUGH, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) — IPG Photonics today announced that from October 6th though October 8th, 2026, IPG Defense will participate in Land Forces 2026 in Perth, Australia to showcase CROSSBOW™ High-Energy Laser (HEL) Systems. This key industry event provides a platform to forge strategic alliances and collaborate to shape the future of the global aerospace and defense market.

IPG Defense Products at Land Forces 2026

In the IPG Defense booth, visitors will experience both the previously released CROSSBOW MINI and the first addition to the new CROSSBOW SE product line, the CROSSBOW SE1 8 kW. Multiple systems will be on display in a typical layered defense arrangement to showcase several deployment scenarios first-hand. Both products share the same scalable architecture and easily integrate with available radar and C2 systems. CROSSBOW MINI systems allow for rapid expeditionary deployment where mobility is critical, and the CROSSBOW SE product line provides increased laser power options for longer range defense against Group I-III UAS threats.

In addition, interactive kiosks will allow attendees to conduct virtual simulations by placing UAS threats and CROSSBOW laser defense systems into scenes to defend critical assets. This interactive experience provides a detailed example of how IPG Defense products can be deployed to defend against UAS swarms in any environment.

Increased Drone Incursions are Fueling Demand

Military installations, government buildings, public arenas, port complexes and critical infrastructures are but a few of the locations where CROSSBOW laser defense systems provide scalable and cost-effective Counter-UAS protection.

“Across the globe, UAS, whether individually or in swarms, continue to threaten both military and civilian critical assets,” said Dr. Ben Allison, Vice President of IPG Defense. “Our presence here at Land Forces is to engage with customers and showcase how our current product lines address their needs, with particular emphasis on demonstrating cooperative engagements with multiple CROSSBOW systems in a layered defense architecture.”

The IPG Defense booth K05 on Level 3 at Land Forces will be staffed with knowledgeable program personnel who are able to discuss laser defense solutions and IPG Defense products.

For more information please visit: IPGDefense.com

About Land Forces

Held biennially over three days, Land Forces is Australia’s premier platform for advancing land-based defense capability as a platform for engagement, featuring a comprehensive international industry exhibition, a specialist conference program with presentations and symposia from leading defense institutions, and extensive networking opportunities.

As the land domain continues to evolve through investment, and strategic partnerships, Land Forces provides a vital interface for stakeholders to explore capability development, supply chain integration, and future force design.

About IPG Defense

IPG Defense is delivering scalable and cost-effective laser Counter-UAS systems for protection of commercial, government and military critical assets and sites from UAS threats.

About IPG Photonics

Innovation is at the heart of IPG Photonics. As a global leader in laser technology, we apply light to transform the world. From manufacturing to medical and beyond, our breakthrough laser solutions power our customers’ success and expand what’s possible.

Contact
Dr. Ben Allison
VP, IPG Defense Products
+1 256-715-5750
ballison@IPGDefense.com

THE WOODLANDS, Texas, Oct. 05, 2026 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 386 homes in September 2026, including 8 currently or previously leased single-family rental homes. This represents a 9.0% increase compared to 354 homes closed in September 2025. Additionally, the Company closed 1,222 homes during the third quarter of 2026, including 33 currently or previously leased single-family rental homes. This represents a 10.4% increase compared to 1,107 homes closed in the third quarter of 2025.

As of September 30, 2026, the Company had 151 active selling communities.

The Company plans to release financial results for the third quarter ended September 30, 2026 before the market opens on Tuesday, November 3, 2026. The Company will hold a conference call at 12:30 p.m. Eastern Time on the same day to discuss the results.

A link to the live audio webcast will be provided through the Investor Relations page of the Company’s website at www.investor.lgihomes.com under the Events and Presentations section.

An archive of the webcast will be available for replay on the Company’s website for one year from the date of the conference call.

About LGI Homes, Inc.

Headquartered in The Woodlands, Texas, LGI Homes, Inc. is a pioneer in the homebuilding industry, successfully applying an innovative and systematic approach to the design, construction and sale of homes across 36 markets in 21 states. LGI Homes has closed over 80,000 homes since its founding in 2003 and has delivered profitable financial results every year. Nationally recognized for its quality construction and exceptional customer service, LGI Homes was named to Newsweek’s list of the World’s Most Trustworthy Companies. LGI Homes’ commitment to excellence extends to its employees, earning the Company numerous workplace awards at the local, state, and national level, including the Top Workplaces USA 2026 Award. For more information about LGI Homes and its unique operating model focused on making the dream of homeownership a reality for families across the nation, please visit the Company’s website at www.lgihomes.com.

CONTACT:
Joshua D. Fattor
Executive Vice President of Finance and Capital Markets
Head of Investor Relations
(281) 210-2586
investorrelations@lgihomes.com

THE WOODLANDS, Texas, Oct. 05, 2026 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 386 homes in September 2026, including 8 currently or previously leased single-family rental homes. This represents a 9.0% increase compared to 354 homes closed in September 2025. Additionally, the Company closed 1,222 homes during the third quarter of 2026, including 33 currently or previously leased single-family rental homes. This represents a 10.4% increase compared to 1,107 homes closed in the third quarter of 2025.

As of September 30, 2026, the Company had 151 active selling communities.

The Company plans to release financial results for the third quarter ended September 30, 2026 before the market opens on Tuesday, November 3, 2026. The Company will hold a conference call at 12:30 p.m. Eastern Time on the same day to discuss the results.

A link to the live audio webcast will be provided through the Investor Relations page of the Company’s website at www.investor.lgihomes.com under the Events and Presentations section.

An archive of the webcast will be available for replay on the Company’s website for one year from the date of the conference call.

About LGI Homes, Inc.

Headquartered in The Woodlands, Texas, LGI Homes, Inc. is a pioneer in the homebuilding industry, successfully applying an innovative and systematic approach to the design, construction and sale of homes across 36 markets in 21 states. LGI Homes has closed over 80,000 homes since its founding in 2003 and has delivered profitable financial results every year. Nationally recognized for its quality construction and exceptional customer service, LGI Homes was named to Newsweek’s list of the World’s Most Trustworthy Companies. LGI Homes’ commitment to excellence extends to its employees, earning the Company numerous workplace awards at the local, state, and national level, including the Top Workplaces USA 2026 Award. For more information about LGI Homes and its unique operating model focused on making the dream of homeownership a reality for families across the nation, please visit the Company’s website at www.lgihomes.com.

CONTACT:
Joshua D. Fattor
Executive Vice President of Finance and Capital Markets
Head of Investor Relations
(281) 210-2586
investorrelations@lgihomes.com

IRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Skyworks Solutions, Inc. (Nasdaq: SWKS) (“Skyworks”), a leading developer, manufacturer and provider of analog and mixed-signal semiconductors and solutions for numerous applications, today announced the expiration and final results of its previously announced offers to holders of Qorvo Notes (as defined herein) to exchange (the “Exchange Offers”) any and all outstanding 4.375% Senior Notes due 2029 (the “2029 Qorvo Notes”) and any and all outstanding 3.375% Senior Notes due 2031 (the “2031 Qorvo Notes” and, together with the 2029 Qorvo Notes, the “Qorvo Notes”) issued by Qorvo, Inc. (“Qorvo”) as set forth in the table below for (1) with respect to the 2029 Qorvo Notes, up to $850,000,000 aggregate principal amount of new 4.375% Senior Notes due 2029 (the “New 2029 Skyworks Notes”) issued by Skyworks and (2) with respect to the 2031 Qorvo Notes, up to $700,000,000 aggregate principal amount of new 3.375% Senior Notes due 2031 (the “New 2031 Skyworks Notes”) issued by Skyworks.

Expiration Date

The Withdrawal Deadline occurred and the Exchange Offers expired at 5:00 p.m., New York City time, on October 5, 2026 (such date and time, the “Expiration Date”). Therefore, any Qorvo Notes validly tendered in the Exchange Offers can no longer be withdrawn and no additional Qorvo Notes may be tendered in the Exchange Offers. Capitalized terms used but not defined herein have the respective meanings set forth in the Prospectus.

Final Results

Global Bondholder Services Corporation, the information agent for the Exchange Offers, has advised Skyworks that as of the Expiration Date, the following respective principal amounts of each series of Qorvo Notes had been validly tendered and not validly withdrawn:

Title of Qorvo Notes /
CUSIP / ISIN No.
Principal Amount
Outstanding
Principal Amount
Tendered
Percentage
4.375% Senior Notes due 2029

Registered:

74736KAH4 /
US74736KAH41

144A:
74736KAG6 /
US74736KAG67

Regulation S:
U7471QAF1 /
USU7471QAF10

$850,000,000 $779,422,000 91.70%
3.375% Senior Notes due 2031

144A:
74736KAJ0 /
US74736KAJ07

Regulation S:
U7471QAJ3 /
USU7471QAJ32

$700,000,000 $647,096,000 92.44%
       

Skyworks expects that it will issue $778,096,000 aggregate principal amount of New 2029 Skyworks Notes and $646,805,000 aggregate principal amount of New 2031 Skyworks Notes on the settlement date.

Settlement Date

The settlement date is expected to occur on or about October 7, 2026.

Additional Information

The Exchange Offers were made pursuant to the terms and subject to the conditions set forth in Skyworks’ registration statement on Form S-4, which was declared effective on May 29, 2026, and the related final prospectus filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 29, 2026 (as it may be amended or supplemented from time to time, the “Prospectus”).

The complete terms and conditions of the Exchange Offers are described in the Prospectus, a copy of which may be obtained by contacting Global Bondholder Services Corporation, the exchange agent and information agent in connection with the Exchange Offers, at (855) 654-2015 (U.S. toll-free) or (212) 430-3774 (banks and brokers) or contact@gbsc-usa.com. Questions regarding the terms and conditions of the Exchange Offers should be directed to the dealer manager, Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282, Collect: (212) 357-1452, Toll-Free: (800) 828-3182.

This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to purchase or sell, any security. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. The Exchange Offers are being made solely pursuant to the Prospectus and only to such persons and in such jurisdictions as is permitted under applicable law.

About Skyworks

Skyworks Solutions, Inc. is empowering the wireless networking revolution. Skyworks is a leading developer, manufacturer and provider of analog and mixed-signal semiconductors and solutions for numerous applications, including aerospace, automotive, broadband, cellular infrastructure, connected home, defense, entertainment and gaming, industrial, medical, smartphone, tablet and wearables.

Skyworks is a global company with engineering, marketing, operations, sales and support facilities located throughout Asia, Europe and North America and is a member of the S&P 500® market index (Nasdaq: SWKS).

Safe Harbor Statement

This press release includes “forward-looking statements.” Forward-looking statements relate to future events, including, but not limited to, the Exchange Offers. These forward-looking statements include information relating to future events, prospects, expectations and results of Skyworks (e.g., certain projections and business trends, including with respect to future sales and revenue, as well as plans for dividend payments). Forward-looking statements can often be identified by words such as “anticipates,” “estimates,” “expects,” “forecasts,” “intends,” “believes,” “plans,” “may,” “will” or “continue,” and similar expressions and variations or negatives of these words. All such statements are subject to certain risks, uncertainties and other important factors that could cause actual results to differ materially and adversely from those projected and may affect Skyworks’ future operating results, financial position and cash flows.

These risks, uncertainties and other important factors include: the risks of doing business internationally, including from trade war or trade protection measures (e.g., tariffs, retaliatory tariffs and other countermeasures or taxes), increased import/export restrictions and controls (e.g., Skyworks’ ability to obtain foreign-sourced raw materials, including from Chinese-based sources, as well as Skyworks’ ability to sell products to certain specified foreign entities only pursuant to a limited export license from the U.S. Department of Commerce), the susceptibility of the semiconductor industry and the markets addressed by Skyworks’, and Skyworks’ customers’, products to economic cycles or changes in economic conditions, including inflation and recession that could result from trade war or trade protection measures; Skyworks’ reliance on a small number of key customers for a large percentage of Skyworks’ sales; decreased gross margins and loss of market share as a result of increased competition; Skyworks’ ability to obtain design wins from customers; Skyworks’ ability to convert design wins into revenue; market acceptance of Skyworks’ products and Skyworks’ customers’ products, including market acceptance of new, emerging technologies such as AI; the mix and volume of phone models sold by Skyworks’ largest customer; the potential impacts on Skyworks’ business, reputation, relationships, results of operations, cash flows and financial condition as a result of the Mergers and related transactions with Qorvo; the possibility that expected benefits related to such transactions with Qorvo may not materialize as expected; Skyworks or Qorvo’s business experiencing disruptions as a result of the Mergers and related transactions or due to transaction-related uncertainty or other factors making it more difficult to maintain relationships with employees, customers, other business partners or governmental entities; Skyworks and Qorvo being unable to successfully implement integration strategies or to achieve expected synergies and operating efficiencies within the expected time-frames or at all; the costs, fees, expenses and other charges related to the Mergers and related transactions with Qorvo, including with respect to any related litigation; reduced flexibility in operating Skyworks’ business as a result of the substantial amount of additional indebtedness Skyworks has incurred and expects to incur in connection with the Mergers and related transactions; delays in the deployment of commercial 5G networks or in consumer adoption of 5G-enabled devices; the volatility of Skyworks’ stock price; changes in laws, regulations and/or policies that could adversely affect Skyworks’ operations and financial results, the economy and Skyworks’ customers’ demand for Skyworks’ products, or the financial markets and Skyworks’ ability to raise capital; fluctuations in Skyworks’ manufacturing yields due to Skyworks’ complex and specialized manufacturing processes; Skyworks’ ability to develop, manufacture and market innovative products, avoid product obsolescence, reduce costs in a timely manner, transition Skyworks’ products to smaller geometry process technologies and achieve higher levels of design integration; the quality of Skyworks’ products and any defect remediation costs; Skyworks’ products’ ability to perform under stringent operating conditions; the availability and pricing of third-party semiconductor foundry, assembly and test capacity, raw materials, including rare earth and similar minerals, supplier components, equipment and shipping and logistics services, including limits on Skyworks’ customers’ ability to obtain such services and materials; risks that Skyworks may not be able to optimize Skyworks’ manufacturing footprint and achieve any financial and operational benefits from such efforts, including reducing fixed costs or improving utilization rates, disruptions to Skyworks’ manufacturing processes, including relating to any relocation of Skyworks’ key facilities; Skyworks’ ability to successfully manage Skyworks’ senior management transitions; Skyworks’ ability to retain, recruit and hire key executives or the departure of any such executives, technical personnel and other employees in the positions and numbers, with the experience and capabilities, and at the compensation levels needed to implement Skyworks’ business and product plans; the timing, rescheduling or cancellation of significant customer orders and Skyworks’ ability, as well as the ability of Skyworks’ customers, to manage inventory; other economic, social, military and geopolitical conditions in the countries in which Skyworks, Skyworks’ customers or Skyworks’ suppliers operate, including the conflicts in Ukraine, Iran and other regions in the Middle East, possible disruptions in transportation networks, and fluctuations in foreign currency exchange rates; the effects of global health crises on business conditions in Skyworks’ industry, including the risk of significant disruptions to Skyworks’ business operations, as well as negative impacts to Skyworks’ financial condition; Skyworks’ ability to prevent theft of Skyworks’ intellectual property, disclosure of confidential information or breaches of Skyworks’ information technology systems; uncertainties of litigation, including Skyworks’ ongoing securities litigation, potential disputes over intellectual property infringement and rights, as well as payments related to the licensing and/or sale of such rights; Skyworks’ ability to continue to grow and maintain an intellectual property portfolio and obtain needed licenses from third parties; Skyworks’ ability to make certain investments and acquisitions, integrate companies Skyworks acquires and/or enter into strategic alliances; and other risks and uncertainties, including those detailed from time to time in Skyworks’ filings with the Securities and Exchange Commission.

The forward-looking statements contained in this press release are made only as of the date hereof, and Skyworks undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Note to Editors: Skyworks and the Skyworks symbol are trademarks or registered trademarks of Skyworks Solutions, Inc., or its subsidiaries in the United States and other countries. Third-party brands and names are for identification purposes only and are the property of their respective owners.

Media Relations:
Constance Griffiths
(949) 230-4867
Constance.Griffiths@skyworks.com
Investor Relations:
Raji Gill
(949) 508-0973
Raji.Gill@skyworks.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.